The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2025 | ALASCCA: adjuvant aspirin in colorectal cancer
The randomized ALASCCA trial (NCT02647099) investigated the effect of low-dose aspirin in patients with stage II and III colorectal cancer and PIK3CA mutations. Anna Martling, MD, PhD, Karolinska Institutet, Stockholm, Sweden, describes how a large cohort of patients genetic mutations within the PIK3CA signaling pathway were given either aspirin or placebo. In summer 2024, the trial met its primary endpoint, demonstrating a significant reduction in recurrence in the PIK3CA-mutated group, with an even stronger effect in patients with other mutations in the same signal pathway. These results were consistent across several subgroups, warranting further scientific evaluation. This interview took place at the ASCO GI Cancers Symposium 2025 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
